Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia
With this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical needs.
The approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of life.
The decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatments in line with the highest international standards and protocols.
Developed by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of ITP.
By increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators.
Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.'
Dr. Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications.
'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.'
She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.'
For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
Follow Emirates 24|7 on Google News.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
43 minutes ago
- Zawya
Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership
From his new base in Dubai, a key international gateway, Hernán will steer Takeda's strategic priorities across diverse, fast-growing EAMEA (Eurasia, the Middle East, and Africa) markets Dubai, United Arab Emirates - Takeda, a global, research and development-driven biopharmaceutical leader, has appointed Hernán Porcile as the new Area Head for its Eurasia, Middle East and Africa (EAMEA) region. Formerly General Manager of Takeda Mexico, Hernán Porcile assumed his new role on July 1, 2025, and is now based in Dubai, United Arab Emirates, from where he will lead the company's strategic developments and accelerate growth across the diverse region. Hernán's appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based healthcare across the region. Building on the company's strong foundation, Hernán will deepen collaboration with key stakeholders, strengthen local systems, and drive innovation through scientific exchange and partnerships, further reinforcing Takeda's long-term commitment to resilient healthcare infrastructure and fostering a lasting impact. ' The EAMEA region's rapidly evolving healthcare landscape presents tremendous opportunities for Takeda, particularly as key markets in the region pursue bold national visions. As a purpose-driven, patient-centric company, we are proud to contribute to these transformative efforts by advancing access to innovative and high-quality healthcare solutions. The region remains a strategic growth priority for Takeda, as we continue to invest in sustainable healthcare solutions and deepen our presence across key markets, ' said Hernán Porcile, Takeda's newly appointed EAMEA Area Head. Hernán joined Takeda in 2009 as Administration and Finance Director in Argentina and has since held several leadership roles, including serving as Head of Takeda Mexico and Colombia. He has also overseen operations across Latin America, covering the Southern Cone, Andean Region, Mexico, and Central America. Throughout his career, he has led key transformation initiatives and strategic projects, with expertise spanning finance, commercial development, and gastroenterology. Notably, he oversaw the successful launch of three critical therapies aimed at improving outcomes for patients with multiple myeloma, hereditary angioedema, and inflammatory bowel disease. Prior to joining Takeda, he spent over 12 years at Schering-Plough. Hernán also serves as Secretary of the Mexican Association of Pharmaceutical Research Industries (AMIIF), where he leads the Clinical Research Commission. He holds a degree in Public Accounting from the University of Morón in Argentina and an MBA in Strategy from the University of Belgrano. With deep expertise in emerging markets and a strong track record of transformational leadership, Hernán is poised to play a pivotal role in advancing Takeda's mission to deliver better health and a brighter future to patients across the Eurasia, Middle East and Africa area. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Zawya
2 hours ago
- Zawya
MoHAP exchanges expertise with visiting delegation as part of the Global Healthcare Leadership Program
UAE, Dubai: The Ministry of Health and Prevention (MoHAP) has received a delegation participating in the Global Healthcare Leadership Program, held in the UAE. The program is organised by the Government Experience Exchange Office of the Ministry of Cabinet Affairs. The visit was attended by His Excellency Dr. Mohammed Salim Al Olama, Undersecretary of MoHAP, alongside Assistant Undersecretaries and senior officials. The delegation's visit aimed to exchange expertise, government administration practices, and share global best practices in healthcare. During the visit, the guests were briefed on MoHAP's key initiatives in digital transformation and innovation within the health sector, as well as the Ministry's efforts to promote preventive care and address health challenges. The visit is part of the UAE's commitment to opening dialogue channels with international health leaders and building healthier societies. It also reflects the UAE's position as a trusted global partner in improving healthcare, driving innovation, and advancing sustainable health security by developing integrated knowledge systems and promoting close collaboration with health leaders and decision-makers across various countries. Comprehensive tour of Centres of Excellence During the visit, the delegation was introduced to the UAE's key achievements in public health, digital transformation of health services, and preventive care. The discussion also touched on how the country is linking its healthcare initiatives to the 2030 Sustainable Development Goals, in line with international efforts to create flexible, equitable, and sustainable health systems. Also addressed were the UAE's strategies to enhance future readiness and tackle global health challenges. The delegation also explored the Ministry's plans for health system governance and were briefed about the coordination between local and federal health authorities. They were provided with an overview of the Ministry's most important strategic and transformational projects and achievements. Additionally, the delegation learnt about the UAE's health regulatory system and the legislative framework that ensures the quality of health services across the country. They also explored the public health system, with a focus on community prevention strategies and proactive responses to epidemics and health emergencies. As part of a field tour, the delegation visited the Ministry's Emergency, Crisis and Disaster Centre, the backbone of the UAE's health preparedness. They also toured the National Centre for Regulating Human Organs and Tissues Transplantation under the Hayat programme, which stands out as a model for ethical and medical leadership. Finally, they visited the Customer Happiness Centre, where they learnt about the UAE's innovative approach to enhancing customer experience and satisfaction in the health sector. Advanced Health Strategies His Excellency Abdulrahman bin Mohamed Al Owais, Minister of Health and Prevention, affirmed that the visit of the delegation, organised in collaboration with the Government Experience Exchange Office at the Ministry of Cabinet Affairs, reflects the international confidence in the UAE's evolving health strategies as well as the global interest in building strategic partnerships with the UAE, especially in digital health and artificial intelligence. 'This is also a testament to the success of the UAE's health system, which is backed by the directives of our wise leadership and national strategies that have positioned the health sector as a central pillar of sustainable development,' the Minister said. Meanwhile, His Excellency Dr. Mohammed Salim Al Olama stated: 'The delegation's visit will further reinforce the UAE's growing role in shaping the future of healthcare worldwide and building international partnerships to exchange knowledge and joint innovation. Leveraging successful experiences, the UAE aims to help create a healthier future for all. 'We will spare no effort to contribute to global health transformation by sharing our expertise in institutional governance and innovation, establishing the UAE as a trusted platform for developing forward-looking health policies.' Al Olama added. Commending UAE's health approach Members of the global delegation commended the UAE's healthcare model, especially its robust digital infrastructure, adaptive legislative framework, and advanced quality systems. They stressed the importance of ongoing collaboration and knowledge-sharing visits, which would play a vital role in creating a globally connected, participatory environment that ensures a healthier future for all societies.
Khaleej Times
6 hours ago
- Khaleej Times
Baraka Real Estate Development convenes free health check-up camp for site employees
In a continuous quest for the well-being of the employees, Baraka Real Estate Development successfully has organised a free health check-up camp for the labourers at its construction sites, with the support of LLH Hospital Musaffah. The initiative underscores Baraka's commitment to corporate social responsibility (CSR) and its efforts to elevate health standards within the real estate and construction industry. The event, held at one of Baraka's active sites, offered workers essential health screening services including blood pressure checks, blood glucose testing, and face-to-face consultations with experienced medical professionals. The goal was to promote early detection of potential health issues, enhance awareness of personal wellness, and ensure frontline workers receive the care and recognition they deserve. 'Each member of our workforce is the backbone of what we construct,' said a spokesperson for Baraka Real Estate Development. 'This programme isn't just about health screenings - it's about honouring the hard work and humanity of every individual on-site, and treating their well-being as an intrinsic business priority.' The LLH Hospital Musaffah medical team delivered the programme with professionalism and empathy, creating a comfortable, informative experience for all participants. Beyond addressing immediate health concerns, the event emphasised the importance of long-term wellness through personalised guidance and preventive care. The initiative was met with enthusiastic participation and appreciation among workers - many of whom have limited access to routine health check-ups. For those requiring further care, timely referrals were arranged to ensure appropriate follow-up. 'Working with medical professionals enables us to provide meaningful value beyond the construction process,' the spokesperson added. 'We see this as a vital part of setting a new benchmark for employee welfare within the real estate development sector.' As the UAE continues to emphasise ethical labour practices and private sector responsibility, Baraka's approach serves as a clear example of how companies can contribute meaningfully to national development goals. The company has confirmed that similar CSR-driven projects are planned as part of its broader commitment to social impact.
